Eberlein, Tempero, Hoppe, Kolodziej, Burns win NCCN awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Comprehensive Cancer Network announced the recipients of a series of awards honoring individuals whose contributions fueled progress in improving and facilitating quality, effective, efficient, and accessible cancer care over the past year:

  • Timothy Eberlein,
    Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

    • Outgoing board of directors chair Eberlein was presented with a Board of Producers Award.

  • Margaret Tempero,
    UCSF Helen Diller Family Comprehensive Cancer Center

    • A Board of Producers Award went to Tempero in honor of her long history of contributions to NCCN, which include chairing the NCCN Clinical Practice Guidelines in Oncology Panel for Pancreatic Cancer

  • Richard Hoppe,
    Stanford Cancer Institute

    • Hoppe received the Rodger Winn Award for expert judgment and commitment to excellence in service of the NCCN Guidelines. As the founding chair of the NCCN Guidelines Panel for Hodgkin Lymphoma, the award is in memory of the first leader of the NCCN Guidelines program.

  • Michael Kolodziej,
    ADVI

    • Kolodziej was awarded as a Partner in Cancer Care in appreciation for his efforts to engage policymakers, employers, payers, and others to improve the accessibility of high-quality cancer care.

  • Jennifer Burns,
    NCCN

    • Burns is a Guidelines Coordinator with NCCN’s Clinical Information Operations team. She was named the Pat Daulerio Employee of the Year Award recipient by her peers at NCCN. The award honors the memory of a longtime employee in NCCN’s meetings department.

Table of Contents

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login